{"ticker": {"uuid": "8ffc2062-0cec-4d11-bf71-0f2dd1d7a68f", "symbol": "ANTX", "name": "AN2 Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to book forward of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides access to the \"Price to book forward\" financial metric for AN2 Therapeutics, Inc. (NASDAQ: ANTX) on the TradingView platform. It highlights that the market is closed and no trades have occurred for this specific metric, with data provided by ICE Data Service", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T14:40:44", "published_display": "14 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 AN2 Therapeutics Inc For: 10 July By Investing.com", "summary": "This article provides details about a Form 4 filing for AN2 Therapeutics Inc. on July 10, 2026. It mentions the company's stock symbol ANTX and includes a Reuters image. The filing date is explicitly stated as July 10, 2026.", "url": "https://ng.investing.com/news/stock-market-news/form-4-an2-therapeutics-inc-for-10-july-93CH-2595707", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T12:39:43", "published_display": "11 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) officer sale covers RSU tax withholding, retains 206,554 shares", "summary": "AN2 Therapeutics officer Joshua M. Eizen sold 5,945 shares of common stock at $4.172 per share on July 8, 2026. This sale was explicitly for tax withholding obligations from Restricted Stock Unit vesting and not a discretionary transaction. After this sale, Eizen still holds 206,", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-1be05fc3af02.html", "source_name": "Stock Titan", "published_at": "2026-07-11T12:10:09", "published_display": "11 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director granted 766 shares in lieu of cash fees", "summary": "AN2 Therapeutics (ANTX) director Patricia A. Martin received a grant of 766 shares of common stock on July 10, 2026. These shares were awarded in lieu of cash fees as per the company's non-employee director compensation policy and vested immediately. This transaction increases he", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-fefa36c307e4.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director receives 2,789-share stock grant in lieu of cash", "summary": "AN2 Therapeutics director Gilbert Lynn Marks received a grant of 2,789 shares of common stock on July 10, 2026, as compensation instead of cash, with the shares vesting immediately. This transaction, made under the company's non-employee director compensation policy, increases Ma", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-af38a10a52a4.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director Aziz Kabeer granted 2,852 shares as fees", "summary": "Aziz Kabeer, a director at AN2 Therapeutics (ANTX), received a grant of 2,852 shares of common stock on July 10, 2026, as compensation for his non-employee director services, issued in lieu of cash. These shares vested immediately, and following this transaction, Kabeer directly ", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-7702563a8ac7.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An2 therapeutics COO Joshua Eizen sells $24,802 in stock", "summary": "Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics, Inc. (NASDAQ:ANTX), sold 5,945 shares of company stock for $24,802 to cover tax withholding obligations from vested RSUs. Following the sale, Eizen still holds 206,554 shares, including various tranches of RSUs and", "url": "https://www.investing.com/news/insider-trading-news/an2-therapeutics-coo-joshua-eizen-sells-24802-in-stock-93CH-4787101", "source_name": "Investing.com", "published_at": "2026-07-10T23:09:19", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An2 therapeutics COO Joshua Eizen sells $24,802 in stock By Investing.com", "summary": "Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics (NASDAQ:ANTX), sold 5,945 shares of company stock worth $24,802 to cover tax obligations from RSU vesting. Following the sale, Eizen still holds 206,554 shares. AN2 Therapeutics, while not yet profitable, has a stro", "url": "https://ca.investing.com/news/stock-market-news/an2-therapeutics-coo-joshua-eizen-sells-24802-in-stock-93CH-4729973", "source_name": "Investing.com Canada", "published_at": "2026-07-10T22:10:09", "published_display": "10 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Slides 5.96% as Biotech Headwinds Pressure ANTX Shares - Naked POC", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVEt5XzJhdmRCQVBpSUxna2tKWHNIbmpLVHZvX2oxSmpiMVhvX0hvV05KYTJDaVd5dzNmOVotVGphSUxxbEJ2QUJoZFdINVZOSmRieGtkUUU5WjJfNXl6RmdsOTBydUpyT2J6U0pDdFJqMkxTWTNjRnpxNHdxbVFQdEM4LXc4UHpKei1wVkM0eGd3M0syN094N0I4Y3VlU24wbVkxVzRNYXR1ZDByclZFOA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T17:41:23+00:00", "published_display": "03 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Growth Benchmark", "summary": "AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 3000E Growth Benchmark. This addition, effective June 29, 2026, reflects the company's growth in the biotechnology and medical research sector. The article also highlights multiple other Russell index inclusion", "url": "https://www.marketscreener.com/news/an2-therapeutics-inc-nasdaqgs-antx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bfe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T23:09:14", "published_display": "29 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 2000 Value Benchmark", "summary": "AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 2000 Value Benchmark. The company is a biopharmaceutical firm focused on developing novel small molecule therapeutics using its boron chemistry platform, with its lead candidate, epetraborole, targeting non-tub", "url": "https://www.marketscreener.com/news/an2-therapeutics-inc-nasdaqgs-antx-added-to-russell-2000-value-benchmark-ce7f5fdfd881f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:09:45", "published_display": "29 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for AN2 Therapeutics, Inc. (ANTX) stock, including analyst price targets and historical performance data. It also addresses frequently asked questions regarding ANTX's current price, volatility, market capitalization, earnings reports, a", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T17:41:16", "published_display": "28 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbXJhUWZlbUZ2UjFSNUk5cHJ5dE9Td3ZOSkhpX2ZmbFpYNDRoNlptTUdUU0d6dFFPV3FTdW16emhxcWRSN2s5R1lWVVBQRkxUdXJUYklCXzNDVkZBMVBhRTlzX3BWdGxtY2NiUldMeDNiZ2JGT1BpNXg1QURicnV0ZFRGbjdwTEx5Y0JhTjFoVFRPSWJIUGZxa3I3MmJvT3NiUVNfb1Bta3phRkkwTVBjRXVscHEyQmxhVUwwWjJjamlVUGN5?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANTX)", "summary": "AN2 Therapeutics, Inc. (NASDAQ: ANTX) stock has seen significant growth, with a 377.06% increase over the last year. Analysts have a consistent price target of $9.00 USD. The company's market capitalization stands at $185.12 million, and its next earnings report is expected on Au", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:46", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides the \"Price to earnings forward\" value for AN2 Therapeutics, Inc. (NASDAQ: ANTX) within the context of TradingView's financial data. It indicates the stock's market status and references the data sources used. The specific financial value is not detailed, but", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:16", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Edges Higher Amid Consolidation Near Support - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQd1FqalpfVDluX1pZamJWTklVZ2s0RTdVMTRUM1MwTW9PVjQtZU8tcV85SExrdExzd21BZEVBN2hSQ1VhaWRPMnRvTjBnV3U1aEhyb2w1SkQ1YXVoUVVTd09WYUtwa1JQSHdMWTZ2MjNNYi1OWEswV3lPX0ZXOXhjNENNblNPOS1vNzdXUzVOMDVuSWJvUVhtQzFDb192RTZ3ZnBGNEhPVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Inc (ANTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for AN2 Therapeutics Inc (ANTX), highlighting an analyst rating of \"Strong Buy\" based on one analyst's assessment. It includes the current stock price, market cap, and projected target price, along with recent and expected EPS figures. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-antx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:13", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Inc (ANTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for AN2 Therapeutics Inc (ANTX) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It provides current stock informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-antx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:44", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides details on the number of shareholders for AN2 Therapeutics, Inc. (NASDAQ: ANTX). It presents a table with \"Period,\" \"Value,\" and \"Change %\" columns, though the data itself is not displayed in the provided content. The information is sourced from ICE Data Ser", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-13T17:09:20", "published_display": "13 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Holds 2026 Annual Stockholder Meeting", "summary": "AN2 Therapeutics, Inc. held its 2026 annual meeting on June 3, 2026, where stockholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm. Despite concerns about weak financial performance, the company's s", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ANTX/pressreleases/2396081/an2-therapeutics-holds-2026-annual-stockholder-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T14:10:04", "published_display": "10 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor", "summary": "AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where a quorum of 63.18% of outstanding shares was present. Shareholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors until the 2029 annual meet", "url": "https://www.stocktitan.net/sec-filings/ANTX/8-k-an2-therapeutics-inc-reports-material-event-be8960f946d6.html", "source_name": "Stock Titan", "published_at": "2026-06-09T22:10:33", "published_display": "09 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics reports positive Chagas disease trial results", "summary": "AN2 Therapeutics Inc. announced positive results from two studies for AN2-502998, an oral treatment for chronic Chagas disease. The drug achieved complete parasite elimination in nonhuman primates and was well-tolerated in a Phase 1 human study, boosting ANTX shares. The company ", "url": "https://www.investing.com/news/company-news/an2-therapeutics-reports-positive-chagas-disease-trial-results-93CH-4726396", "source_name": "Investing.com", "published_at": "2026-06-04T22:09:54", "published_display": "04 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (Nasdaq: ANTX) posts strong early Chagas trial data", "summary": "AN2 Therapeutics announced positive early-stage data for its oral CPSF3 inhibitor AN2-502998 for chronic Chagas disease. A 28-day nonhuman primate study showed 100% parasite elimination, and a Phase 1 human trial demonstrated a favorable safety and tolerability profile. The compa", "url": "https://www.stocktitan.net/sec-filings/ANTX/8-k-an2-therapeutics-inc-reports-material-event-8c62da165782.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:15:35", "published_display": "04 Jun 2026 20:15", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Says Chagas Disease Drug Shows Positive Preclinical, Early Human Data", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/an2-therapeutics-says-chagas-disease-120403565.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:04:03+00:00", "published_display": "04 Jun 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease", "summary": "AN2 Therapeutics announced positive results for its oral drug AN2-502998, intended for chronic Chagas disease. Studies in nonhuman primates showed 100% parasitic elimination after 28 days of treatment, and a Phase 1 human study demonstrated a favorable safety profile. These findi", "url": "https://www.businesswire.com/news/home/20260604006839/en/AN2-Therapeutics-Reports-Positive-Enabling-Data-Supporting-Advancement-of-Oral-AN2-502998-to-Phase-2-Study-for-Chronic-Chagas-Disease", "source_name": "Business Wire", "published_at": "2026-06-04T11:10:35", "published_display": "04 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes", "summary": "AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams sold 265 shares of common stock at $4.43 per share. This transaction was not a discretionary sale but rather a routine tax-related event to satisfy withholding obligations from vested Restricted Stock Units (RSUs", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-a4ddc07ada49.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:19:36", "published_display": "02 Jun 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Slides 2.9% as Shares Test Key Support Near $4.11 - Regression Channel", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOYlkyQ21YSjNVRHV1cUtuS1A5RzhhcWRGc1RPQ3c5Sjdia3JnalEtVjhHNy1STFJlZ1JOUG1GSnJxQXZJSlA4TXlFVkkxV0w3MkhPV2xoS1RGamNoeXg1dzhmdzVEeDRNQk9DOFBxcHlYam5wbFRsWVJiTlhkaGRUMmtnQkRxU0lvSTNNNXpfMHFGM0ZLRHczZUVseTlsZ05qR00tcW0zNGFNSEwwbXpkX2Zvd2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Slides 2.7% as Shares Test Support Near $4.27 - Wyckoff Distribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQUGJnN3JWcnBQQk55TlJqVnFmVGtURTBXSkw4aVdFOEdMODYwV1VjdWIyMDlDR3pLYU5YZFhuOEZxLUYybXNNTENwRWZCMGFWWG9jS3p3V2ZNeEhmbEJKRlFWc2oxT0xzSzhjQUpZLTZzSEVuM2prZnBmOHJpZ3p0RXpoNTdmRjBhMkF2cTBKRGpBQ3ZGRjZ6MEd1UE5lMEtQTF8tVk4wZm9uT21a?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference", "summary": "AN2 Therapeutics, Inc. announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET. The company, a clinical-stage biopharmaceutical firm using boron chemistry, will also m", "url": "http://www.businesswire.com/news/home/20260521162598/en/AN2-Therapeutics-to-Present-at-2026-Jefferies-Global-Healthcare-Conference/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT", "source_name": "Business Wire", "published_at": "2026-05-21T12:09:45", "published_display": "21 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CEO Eric Easom to speak at Jefferies Global Healthcare Conference", "summary": "AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET. The company, a clinical-stage biopharmaceutical firm focusing on novel s", "url": "https://www.stocktitan.net/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-dvdoo6jc4og7.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:08:57", "published_display": "21 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Almitas Capital holds 4.1% of AN2 Therapeutics (NASDAQ: ANTX)", "summary": "Almitas Capital LLC has reported a beneficial ownership of 1,479,129 shares in AN2 Therapeutics (NASDAQ: ANTX), representing a 4.1% stake in the company. This disclosure was made via an amended Schedule 13G/A filing, signed by Ronald Mass on May 15, 2026. Almitas Capital holds so", "url": "https://www.stocktitan.net/sec-filings/ANTX/schedule-13g-a-an2-therapeutics-inc-amended-passive-investment-disclo-0fdc67752d8f.html", "source_name": "Stock Titan", "published_at": "2026-05-16T01:40:35", "published_display": "16 May 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Correction: Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/correction-leerink-partners-upgrades-an2-110614351.html", "source_name": "MT Newswires", "published_at": "2026-05-14T11:06:14+00:00", "published_display": "14 May 2026 11:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "AN2 Therapeutics Raises $40 Million in Private Placement of Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPVXNYSHlyZDlWUVNIRmVtNGFOVkRhWlFmX1YyaEVZWkludFNPX3BGS0wzaTBock90M0Y1Q3JkRnFDdmh2aTlYdHlOOENxQjJad24zUjNrSG5SeWlfYi1TZmlxTjNPbTE5ZHRCcXF6c1JtSFRicXhvVjI5QkJEVDNodGJRcHZXXzlZTXgxOTJFOWRfZnZjcFNBR1NSd0s4OVNVT1NLVW9QS3M0WVMxb1gzM2s1UXhjRFUtXzA0LTQ3OFlOOU9qbFBidmhVcy00ZjVYNHU1OENTMW16UTBBWl9IbGtUQTJUdw?oc=5", "source_name": "TradingView", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Announces $40 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3UxZFZIVHpFeFU4OW9ILUVNdnVDaWc2UnBWdU11SGRiSVhiTk84ZzFzREpRbVNqQWJLbmRYTGFfR3JNckx5ZkVFNDNiMHFpOGdIREprWEp0NGxobWlvT3lZUjVmUFFydVVYT2tKYWlTMHc3b1Vxdzdtd3lXSndsMFdUbXpld2hCMkVhekxxWVNVWnhIRDBzbFNQLUtKU0NHQ0tWa0pjVm5aeXZiYzFRQVpNcXFHNDJ2WHBhamFmWFBTYVU?oc=5", "source_name": "Business Wire", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics: $40 Million Private Placement Financing Announced", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPM0V3c0lSTnJ6SF92YzZDRi1fWnFXWWs0bjVVVUlwMldSa0d2MjBoZnkzSHJtVXh1Y0Z0Wml5NlJkU1hvMlRvdXlocUpCMjFGZk43d3d5TjM2TVpGMjUzUDlUdS1fbjFhbGljN2pyZTF0Y1QxTG9yTHlpWjVHMmZ6dG1xNWNVNUJBSDlyLXhR0gGTAUFVX3lxTE02eUtIV3pVaUZGa1hQc1JNbkRQUi1QQmdMU3FDZloxb3I0elFBWUpMaElaRF96OUtjSEtzejNfbmw5SmUya050MEVDMlpMTE80SEtPaXE4QU0tcVhpTHF1R2t5ZEI0Z0IwblRTNDFHbkhLVVlJUUpPTFp1Zk1mNGh0eUVXNFFWNmZ4NUl3VjROaGpwWQ?oc=5", "source_name": "Pulse 2.0", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy AN2 Therapeutics (ANTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE50MmhoQWl3TUVPdmJQWXlfSERZenNJNFhTejlXSFJuWmY3OHAxNlJtZFZROW5qUXhqSElwRndPRUVfazAyenZxQVJzRHBHM2gxdWJyZng2WXhHdnFKWl9vOFNJWS1YQXBwTEhsQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1WSHRTRHE3LVRlVzJ0UjJCY3pYYnh1TjZNbmFlVnpuc2R5ZFFjWUQwX1ptc2QxeW5KbDZPdnVQLTJtZk5sck9MZG01NFRfeFZXVkhB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:19:59+00:00", "published_display": "25 Apr 2025 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iterum Therapeutics Plc (ITRM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5Ib3dWZzdpNDFYVUgxakxkM0pLQU5VbnNjUnhCWXg2VTJuS253RmxsNzdvMUxzUjBVaERfckxQQjg0dzNjWEZxcXlUdjI4MlFRdGRj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:46:25+00:00", "published_display": "24 Apr 2025 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides access to the \"Price to book forward\" financial metric for AN2 Therapeutics, Inc. (NASDAQ: ANTX) on the TradingView platform. It highlights that the market is closed and no trades have occurred for this specific metric, with data provided by ICE Data Service", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T14:40:44", "published_display": "14 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 AN2 Therapeutics Inc For: 10 July By Investing.com", "summary": "This article provides details about a Form 4 filing for AN2 Therapeutics Inc. on July 10, 2026. It mentions the company's stock symbol ANTX and includes a Reuters image. The filing date is explicitly stated as July 10, 2026.", "url": "https://ng.investing.com/news/stock-market-news/form-4-an2-therapeutics-inc-for-10-july-93CH-2595707", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T12:39:43", "published_display": "11 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) officer sale covers RSU tax withholding, retains 206,554 shares", "summary": "AN2 Therapeutics officer Joshua M. Eizen sold 5,945 shares of common stock at $4.172 per share on July 8, 2026. This sale was explicitly for tax withholding obligations from Restricted Stock Unit vesting and not a discretionary transaction. After this sale, Eizen still holds 206,", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-1be05fc3af02.html", "source_name": "Stock Titan", "published_at": "2026-07-11T12:10:09", "published_display": "11 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director granted 766 shares in lieu of cash fees", "summary": "AN2 Therapeutics (ANTX) director Patricia A. Martin received a grant of 766 shares of common stock on July 10, 2026. These shares were awarded in lieu of cash fees as per the company's non-employee director compensation policy and vested immediately. This transaction increases he", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-fefa36c307e4.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director receives 2,789-share stock grant in lieu of cash", "summary": "AN2 Therapeutics director Gilbert Lynn Marks received a grant of 2,789 shares of common stock on July 10, 2026, as compensation instead of cash, with the shares vesting immediately. This transaction, made under the company's non-employee director compensation policy, increases Ma", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-af38a10a52a4.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) director Aziz Kabeer granted 2,852 shares as fees", "summary": "Aziz Kabeer, a director at AN2 Therapeutics (ANTX), received a grant of 2,852 shares of common stock on July 10, 2026, as compensation for his non-employee director services, issued in lieu of cash. These shares vested immediately, and following this transaction, Kabeer directly ", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-7702563a8ac7.html", "source_name": "Stock Titan", "published_at": "2026-07-11T00:09:19", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An2 therapeutics COO Joshua Eizen sells $24,802 in stock", "summary": "Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics, Inc. (NASDAQ:ANTX), sold 5,945 shares of company stock for $24,802 to cover tax withholding obligations from vested RSUs. Following the sale, Eizen still holds 206,554 shares, including various tranches of RSUs and", "url": "https://www.investing.com/news/insider-trading-news/an2-therapeutics-coo-joshua-eizen-sells-24802-in-stock-93CH-4787101", "source_name": "Investing.com", "published_at": "2026-07-10T23:09:19", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An2 therapeutics COO Joshua Eizen sells $24,802 in stock By Investing.com", "summary": "Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics (NASDAQ:ANTX), sold 5,945 shares of company stock worth $24,802 to cover tax obligations from RSU vesting. Following the sale, Eizen still holds 206,554 shares. AN2 Therapeutics, while not yet profitable, has a stro", "url": "https://ca.investing.com/news/stock-market-news/an2-therapeutics-coo-joshua-eizen-sells-24802-in-stock-93CH-4729973", "source_name": "Investing.com Canada", "published_at": "2026-07-10T22:10:09", "published_display": "10 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Slides 5.96% as Biotech Headwinds Pressure ANTX Shares - Naked POC", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQVEt5XzJhdmRCQVBpSUxna2tKWHNIbmpLVHZvX2oxSmpiMVhvX0hvV05KYTJDaVd5dzNmOVotVGphSUxxbEJ2QUJoZFdINVZOSmRieGtkUUU5WjJfNXl6RmdsOTBydUpyT2J6U0pDdFJqMkxTWTNjRnpxNHdxbVFQdEM4LXc4UHpKei1wVkM0eGd3M0syN094N0I4Y3VlU24wbVkxVzRNYXR1ZDByclZFOA?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-03T17:41:23+00:00", "published_display": "03 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Growth Benchmark", "summary": "AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 3000E Growth Benchmark. This addition, effective June 29, 2026, reflects the company's growth in the biotechnology and medical research sector. The article also highlights multiple other Russell index inclusion", "url": "https://www.marketscreener.com/news/an2-therapeutics-inc-nasdaqgs-antx-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bfe25", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T23:09:14", "published_display": "29 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 2000 Value Benchmark", "summary": "AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 2000 Value Benchmark. The company is a biopharmaceutical firm focused on developing novel small molecule therapeutics using its boron chemistry platform, with its lead candidate, epetraborole, targeting non-tub", "url": "https://www.marketscreener.com/news/an2-therapeutics-inc-nasdaqgs-antx-added-to-russell-2000-value-benchmark-ce7f5fdfd881f222", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:09:45", "published_display": "29 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for AN2 Therapeutics, Inc. (ANTX) stock, including analyst price targets and historical performance data. It also addresses frequently asked questions regarding ANTX's current price, volatility, market capitalization, earnings reports, a", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T17:41:16", "published_display": "28 Jun 2026 17:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPbXJhUWZlbUZ2UjFSNUk5cHJ5dE9Td3ZOSkhpX2ZmbFpYNDRoNlptTUdUU0d6dFFPV3FTdW16emhxcWRSN2s5R1lWVVBQRkxUdXJUYklCXzNDVkZBMVBhRTlzX3BWdGxtY2NiUldMeDNiZ2JGT1BpNXg1QURicnV0ZFRGbjdwTEx5Y0JhTjFoVFRPSWJIUGZxa3I3MmJvT3NiUVNfb1Bta3phRkkwTVBjRXVscHEyQmxhVUwwWjJjamlVUGN5?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANTX)", "summary": "AN2 Therapeutics, Inc. (NASDAQ: ANTX) stock has seen significant growth, with a 377.06% increase over the last year. Analysts have a consistent price target of $9.00 USD. The company's market capitalization stands at $185.12 million, and its next earnings report is expected on Au", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:46", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides the \"Price to earnings forward\" value for AN2 Therapeutics, Inc. (NASDAQ: ANTX) within the context of TradingView's financial data. It indicates the stock's market status and references the data sources used. The specific financial value is not detailed, but", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:16", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Edges Higher Amid Consolidation Near Support - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQd1FqalpfVDluX1pZamJWTklVZ2s0RTdVMTRUM1MwTW9PVjQtZU8tcV85SExrdExzd21BZEVBN2hSQ1VhaWRPMnRvTjBnV3U1aEhyb2w1SkQ1YXVoUVVTd09WYUtwa1JQSHdMWTZ2MjNNYi1OWEswV3lPX0ZXOXhjNENNblNPOS1vNzdXUzVOMDVuSWJvUVhtQzFDb192RTZ3ZnBGNEhPVQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Inc (ANTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for AN2 Therapeutics Inc (ANTX), highlighting an analyst rating of \"Strong Buy\" based on one analyst's assessment. It includes the current stock price, market cap, and projected target price, along with recent and expected EPS figures. T", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-antx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:13", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Inc (ANTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for AN2 Therapeutics Inc (ANTX) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It provides current stock informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-antx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:44", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX", "summary": "This article provides details on the number of shareholders for AN2 Therapeutics, Inc. (NASDAQ: ANTX). It presents a table with \"Period,\" \"Value,\" and \"Change %\" columns, though the data itself is not displayed in the provided content. The information is sourced from ICE Data Ser", "url": "https://www.tradingview.com/symbols/NASDAQ-ANTX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-13T17:09:20", "published_display": "13 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Holds 2026 Annual Stockholder Meeting", "summary": "AN2 Therapeutics, Inc. held its 2026 annual meeting on June 3, 2026, where stockholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm. Despite concerns about weak financial performance, the company's s", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ANTX/pressreleases/2396081/an2-therapeutics-holds-2026-annual-stockholder-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T14:10:04", "published_display": "10 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor", "summary": "AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where a quorum of 63.18% of outstanding shares was present. Shareholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors until the 2029 annual meet", "url": "https://www.stocktitan.net/sec-filings/ANTX/8-k-an2-therapeutics-inc-reports-material-event-be8960f946d6.html", "source_name": "Stock Titan", "published_at": "2026-06-09T22:10:33", "published_display": "09 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics reports positive Chagas disease trial results", "summary": "AN2 Therapeutics Inc. announced positive results from two studies for AN2-502998, an oral treatment for chronic Chagas disease. The drug achieved complete parasite elimination in nonhuman primates and was well-tolerated in a Phase 1 human study, boosting ANTX shares. The company ", "url": "https://www.investing.com/news/company-news/an2-therapeutics-reports-positive-chagas-disease-trial-results-93CH-4726396", "source_name": "Investing.com", "published_at": "2026-06-04T22:09:54", "published_display": "04 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (Nasdaq: ANTX) posts strong early Chagas trial data", "summary": "AN2 Therapeutics announced positive early-stage data for its oral CPSF3 inhibitor AN2-502998 for chronic Chagas disease. A 28-day nonhuman primate study showed 100% parasite elimination, and a Phase 1 human trial demonstrated a favorable safety and tolerability profile. The compa", "url": "https://www.stocktitan.net/sec-filings/ANTX/8-k-an2-therapeutics-inc-reports-material-event-8c62da165782.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:15:35", "published_display": "04 Jun 2026 20:15", "sentiment": "positive", "sentiment_pct": 85, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Says Chagas Disease Drug Shows Positive Preclinical, Early Human Data", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/an2-therapeutics-says-chagas-disease-120403565.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:04:03+00:00", "published_display": "04 Jun 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease", "summary": "AN2 Therapeutics announced positive results for its oral drug AN2-502998, intended for chronic Chagas disease. Studies in nonhuman primates showed 100% parasitic elimination after 28 days of treatment, and a Phase 1 human study demonstrated a favorable safety profile. These findi", "url": "https://www.businesswire.com/news/home/20260604006839/en/AN2-Therapeutics-Reports-Positive-Enabling-Data-Supporting-Advancement-of-Oral-AN2-502998-to-Phase-2-Study-for-Chronic-Chagas-Disease", "source_name": "Business Wire", "published_at": "2026-06-04T11:10:35", "published_display": "04 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes", "summary": "AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams sold 265 shares of common stock at $4.43 per share. This transaction was not a discretionary sale but rather a routine tax-related event to satisfy withholding obligations from vested Restricted Stock Units (RSUs", "url": "https://www.stocktitan.net/sec-filings/ANTX/form-4-an2-therapeutics-inc-insider-trading-activity-a4ddc07ada49.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:19:36", "published_display": "02 Jun 2026 20:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Slides 2.9% as Shares Test Key Support Near $4.11 - Regression Channel", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOYlkyQ21YSjNVRHV1cUtuS1A5RzhhcWRGc1RPQ3c5Sjdia3JnalEtVjhHNy1STFJlZ1JOUG1GSnJxQXZJSlA4TXlFVkkxV0w3MkhPV2xoS1RGamNoeXg1dzhmdzVEeDRNQk9DOFBxcHlYam5wbFRsWVJiTlhkaGRUMmtnQkRxU0lvSTNNNXpfMHFGM0ZLRHczZUVseTlsZ05qR00tcW0zNGFNSEwwbXpkX2Zvd2c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Slides 2.7% as Shares Test Support Near $4.27 - Wyckoff Distribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQUGJnN3JWcnBQQk55TlJqVnFmVGtURTBXSkw4aVdFOEdMODYwV1VjdWIyMDlDR3pLYU5YZFhuOEZxLUYybXNNTENwRWZCMGFWWG9jS3p3V2ZNeEhmbEJKRlFWc2oxT0xzSzhjQUpZLTZzSEVuM2prZnBmOHJpZ3p0RXpoNTdmRjBhMkF2cTBKRGpBQ3ZGRjZ6MEd1UE5lMEtQTF8tVk4wZm9uT21a?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference", "summary": "AN2 Therapeutics, Inc. announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET. The company, a clinical-stage biopharmaceutical firm using boron chemistry, will also m", "url": "http://www.businesswire.com/news/home/20260521162598/en/AN2-Therapeutics-to-Present-at-2026-Jefferies-Global-Healthcare-Conference/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT", "source_name": "Business Wire", "published_at": "2026-05-21T12:09:45", "published_display": "21 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech CEO Eric Easom to speak at Jefferies Global Healthcare Conference", "summary": "AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM ET. The company, a clinical-stage biopharmaceutical firm focusing on novel s", "url": "https://www.stocktitan.net/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-dvdoo6jc4og7.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:08:57", "published_display": "21 May 2026 11:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Almitas Capital holds 4.1% of AN2 Therapeutics (NASDAQ: ANTX)", "summary": "Almitas Capital LLC has reported a beneficial ownership of 1,479,129 shares in AN2 Therapeutics (NASDAQ: ANTX), representing a 4.1% stake in the company. This disclosure was made via an amended Schedule 13G/A filing, signed by Ronald Mass on May 15, 2026. Almitas Capital holds so", "url": "https://www.stocktitan.net/sec-filings/ANTX/schedule-13g-a-an2-therapeutics-inc-amended-passive-investment-disclo-0fdc67752d8f.html", "source_name": "Stock Titan", "published_at": "2026-05-16T01:40:35", "published_display": "16 May 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Correction: Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/correction-leerink-partners-upgrades-an2-110614351.html", "source_name": "MT Newswires", "published_at": "2026-05-14T11:06:14+00:00", "published_display": "14 May 2026 11:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Raises $40 Million in Private Placement of Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPVXNYSHlyZDlWUVNIRmVtNGFOVkRhWlFmX1YyaEVZWkludFNPX3BGS0wzaTBock90M0Y1Q3JkRnFDdmh2aTlYdHlOOENxQjJad24zUjNrSG5SeWlfYi1TZmlxTjNPbTE5ZHRCcXF6c1JtSFRicXhvVjI5QkJEVDNodGJRcHZXXzlZTXgxOTJFOWRfZnZjcFNBR1NSd0s4OVNVT1NLVW9QS3M0WVMxb1gzM2s1UXhjRFUtXzA0LTQ3OFlOOU9qbFBidmhVcy00ZjVYNHU1OENTMW16UTBBWl9IbGtUQTJUdw?oc=5", "source_name": "TradingView", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics Announces $40 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3UxZFZIVHpFeFU4OW9ILUVNdnVDaWc2UnBWdU11SGRiSVhiTk84ZzFzREpRbVNqQWJLbmRYTGFfR3JNckx5ZkVFNDNiMHFpOGdIREprWEp0NGxobWlvT3lZUjVmUFFydVVYT2tKYWlTMHc3b1Vxdzdtd3lXSndsMFdUbXpld2hCMkVhekxxWVNVWnhIRDBzbFNQLUtKU0NHQ0tWa0pjVm5aeXZiYzFRQVpNcXFHNDJ2WHBhamFmWFBTYVU?oc=5", "source_name": "Business Wire", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics: $40 Million Private Placement Financing Announced", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPM0V3c0lSTnJ6SF92YzZDRi1fWnFXWWs0bjVVVUlwMldSa0d2MjBoZnkzSHJtVXh1Y0Z0Wml5NlJkU1hvMlRvdXlocUpCMjFGZk43d3d5TjM2TVpGMjUzUDlUdS1fbjFhbGljN2pyZTF0Y1QxTG9yTHlpWjVHMmZ6dG1xNWNVNUJBSDlyLXhR0gGTAUFVX3lxTE02eUtIV3pVaUZGa1hQc1JNbkRQUi1QQmdMU3FDZloxb3I0elFBWUpMaElaRF96OUtjSEtzejNfbmw5SmUya050MEVDMlpMTE80SEtPaXE4QU0tcVhpTHF1R2t5ZEI0Z0IwblRTNDFHbkhLVVlJUUpPTFp1Zk1mNGh0eUVXNFFWNmZ4NUl3VjROaGpwWQ?oc=5", "source_name": "Pulse 2.0", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy AN2 Therapeutics (ANTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE50MmhoQWl3TUVPdmJQWXlfSERZenNJNFhTejlXSFJuWmY3OHAxNlJtZFZROW5qUXhqSElwRndPRUVfazAyenZxQVJzRHBHM2gxdWJyZng2WXhHdnFKWl9vOFNJWS1YQXBwTEhsQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-04T07:00:00+00:00", "published_display": "04 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AN2 Therapeutics (ANTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1WSHRTRHE3LVRlVzJ0UjJCY3pYYnh1TjZNbmFlVnpuc2R5ZFFjWUQwX1ptc2QxeW5KbDZPdnVQLTJtZk5sck9MZG01NFRfeFZXVkhB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:19:59+00:00", "published_display": "25 Apr 2025 00:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iterum Therapeutics Plc (ITRM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5Ib3dWZzdpNDFYVUgxakxkM0pLQU5VbnNjUnhCWXg2VTJuS253RmxsNzdvMUxzUjBVaERfckxQQjg0dzNjWEZxcXlUdjI4MlFRdGRj?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T22:46:25+00:00", "published_display": "24 Apr 2025 22:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 47, "sentiment_summary": {"positive": 14, "negative": 1, "neutral": 32, "score": 56, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 4.5, "latest_week": "2026-07-10", "one_week_move": 1.8, "four_week_move": -5.1, "twelve_week_move": 24.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.050376, "market_dynamics_buy_signal": false, "relative_strength": 75.430894, "fair_value_gap": -1.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.7469, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.8% over one week, -5.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 7}, {"label": "Market source", "count": 5}, {"label": "dars.gov.et", "count": 3}, {"label": "Business Wire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 15}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.8% over one week, -5.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of AN2 Therapeutics, Inc. \u2013 NASDAQ:ANTX"}], "updated_at": "2026-07-16T06:04:30.809807+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}